April 19, 2022 7:47am

We can only hope for algorithmic for some oversold recognition; however, investors steer clear until sentiment turns hopefully after earnings’ cycle which begins 4/28 with Alnylam Pharmaceuticals (ALNY)

The Biostage (BSTG) Chronicles: Question, is the company a Beijing, China “concubine” as to the pumping of the share price and volume? What would make a U.S. investor step-up with all the “inhibitors” to its public listing share pricing existence?

Pre-open indications: 5 BUY indications and 1 Pimp/Pump/Promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.01% (-3 points), S&P futures are DOWN -0.07% (-3 points) and NASDAQ futures are DOWN -0.14% (-20 points) early in the pre-open


Stock futures are slipping and barely jumping in Tuesday’s pre-market, expect a negative open,

European markets were lower after the long Easter weekend as the overlapping crises of the war in Ukraine, pandemic and inflation cloud the global economic outlook.

Asia-Pacific markets were mixed, as investors watched for market reaction to China’s central bank announcing financial support for Covid-hit sectors; Australia and Japan markets advanced.



Last night, Monday; the Dow closed DOWN -39.54 points (-0.11%); the S&P closed DOWN 0.90- points (-0.02%) while the Nasdaq closed DOWN -18.72 points (-0.14%).

The major indexes have been grinding lower as Q1 earnings season heats up. Today, Johnson & Johnson (JNJ) will report its Q results.

JNJ reported mixed quarterly results, with its earnings per share topping earnings expectations while revenue missed analyst estimates. The pharmaceutical company also lowered its earnings guidance for 2022.

Just remember, the Fed’s moves have and next steps will cause high volatility in the bond market weighing on share pricing in coming weeks.

Economic Data Docket: housing market with housing starts and building permits for March.


Last night’s RegMed Investors’ (RMi) closing bell post: “Why the slide … More downside “correction” or as I say sentiment infection or rejection” …  https://www.regmedinvestors.com/articles/12393

Ebb and flow –

Q2/22 –1 holiday, 3 positive and 8 negative close


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS


Alnylam Pharmaceuticals (ALNY) closed down -$10.66 with a positive +$0.95 or +0.61% pre-open indication,

Beam Therapeutics (BEAM) closed down -$2.42 with a positive +$2.01 or +4.57% pre-open indication

uniQure NV (QURE) closed down -$1.43 to $17.32 with a positive +$0.44 or +2.54% pre-open indication.

CRISPR Therapeutics (CRSP) closed down -$3.45 with a positive +$0.71 or +1.21% pre-open indication.

Vericel (VCEL) closed down -$1.60 to $35.16 with a positive +$0.52 or +1.48% pre-open indication,


Pimp/Pump and Promote:

Biostage (BSTG) closed down Monday -$0.48 with 2,873 shares traded after Thursday’s -$0.02 to $5.98 after Wednesday ’s +$0.50 with 2,851 shares traded after last Tuesday’s -$0.30 with 1,634 shares traded.

  • WARNING:  WHY BUY this equity with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a precarious financial position dependent on a possible cash infusion? Also, WHY the pump of the volume to gain share appreciation – they have to reverse the multiple private placements (the priciest was $4.71) for a potential/proposed stock offering.


The BOTTOM LINE: State the obvious, investors are NOT in control of daily market driven sector appreciation or downward dives.

I try to keep it simple … and short!

To expect a payday; volatility and low volume are part of the equation.

I am still, in the here and now, the cell and gene therapy sector will be fluttering; we are about to enter the earnings’ zone!

Earnings’ season is upon us as Alnylam Pharmaceuticals (ALNY) reports Thursday,4/28 followed so far by Sage Therapeutics (SAGE) on 5/3 and AxoGen (AXGN) on 5/4.

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Share pricing intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.